Classical 3␤-hydroxysteroid dehydrogenase/⌬ 5 -⌬ 4 isomerase (3␤HSD) deficiency is a form of congenital adrenal hyperplasia that impairs steroidogenesis in both the adrenals and gonads resulting from mutations in the HSD3B2 gene and causing various degrees of saltwasting in both sexes and incomplete masculinization of the external genitalia in genetic males. To identify the molecular lesion(s) in the HSD3B2 gene in the 11 patients from the seven new families suffering from classical 3␤HSD deficiency, the complete nucleotide sequence of the whole coding region and exon-intron splicing boundaries of this gene was determined by direct sequencing. Five of these families were referred to Morel's molecular diagnostics laboratory in France, whereas the two other families were investigated by Peter's group in Germany. Functional characterization studies were performed by Simard's group in Canada. Following transient expression in 293 cells of each of the mutant recombinant proteins generated by site-directed mutagenesis, the effect of the 25 mutations on enzyme activity was assessed by incubating intact cells in culture with 10 nM [ 14 C]-DHEA as substrate. The stability of the mutant proteins has been investigated using a combination of Northern and Western blot analyses, as well as an in vitro transcription/translation assay using rabbit reticulocyte lysates. The present report describes the identification of 8 mutations, in seven new families with individuals suffering from classical 3␤HSD deficiency, thus increasing the number of known HSD3B2 mutations involved in this autosomal recessive disorder to 31 (1 splicing, 1 in-frame deletion, 3 nonsense, 4 frameshift and 22 missense mutations). In addition to the mutations reported here in these new families, we have also investigated for the first time the functional significance of previously reported missense mutations and or sequence variants namely, A82T, A167V, L173R, L205P, S213G and K216E, P222H, T259M, and T259R, which have not previously been functionally characterized. Furthermore, their effects have been compared with those of the 10 previously reported mutant enzymes to provide a more consistent and comprehensive study. The present results are in accordance with the prediction that no functional 3␤HSD type 2 isoenzyme is expressed in the adrenals and gonads of the patients suffering from a severe salt-wasting form of CAH due to classical 3␤HSD deficiency. Whereas the nonsalt-losing form also results from missense mutation(s) in the HSD3B2 gene, which cause an incomplete loss in enzyme activity, thus leaving sufficient enzymatic activity to prevent salt wasting. The functional data described in the present study concerning the sequence variants A167V, S213G, K216E and L236S, which were detected with premature pubarche or hyperandrogenic adolescent girls suspected to be affected from nonclassical 3␤HSD deficiency, coupled with the previous studies reporting that no mutations were found in both HSD3B1 and/or HSD3B2 genes in such patients strongly support the conclusion that this disorder does not result from a mutant 3␤HSD isoenzyme. The present study provides biochemical evidence supporting the involvement of a new molecular mechanism in classical 3␤HSD deficiency involving protein instability and further illustrates the complexity of the genotype-phenotype relationships of this disease, in addition to providing further valuable information concerning the structure-function relationships of the 3␤HSD superfamily. (J Clin Endocrinol Metab 84: 4410 -4425, 1999) 
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Classical 3␤HSD deficiency results from mutations in the HSD3B2 gene, whereas the HSD3B1 gene is normal in these patients, and is responsible for a severe form of congenital adrenal hyperplasia (CAH). Since the first reports by Bongiovanni (16, 17) , many patients of both sexes have been described, and the heterogeneity of the clinical presentation demonstrated. In contrast to the two most frequent causes of CAH, 21-hydroxylase and 11␤-hydroxylase deficiencies, which are adrenal defects, the severe form of 3␤HSD deficiency impairs steroidogenesis in both the adrenals and the gonads, resulting in decreased secretion by these tissues of not only cortisol and aldosterone, but also of PROG, androgens, and estrogens (18 -24 and references therein).
Newborns affected by CAH due to classic 3␤HSD deficiency exhibit varying degrees of salt wasting associated with male pseudohermaphroditism (18 -25 and references therein). The expected severe inhibition of T biosynthesis by the fetal testis resulting in a marked decrease in 3␤HSD activity provides an explanation for the incomplete masculinization of the external genitalia seen in the male patients studied. Furthermore, males affected with pseudohermaphroditism and complete or partial 3␤HSD deficiency have intact Wolffian duct structures, including vas deferens. This is also the case in 17␤HSD type 3 deficiency as well as 5␣-reductase type 2 deficiency, which is consistent with the hypothesis that a principal effect of 3␤HSD deficiency is to reduce the formation of dihydrotestosterone below the level required for the development of external genitalia (22, 25) . On the other hand, complete or partial inhibition of 3␤HSD activity in the adrenals and ovaries was not accompanied by a noticeable alteration in the differentiation of the external genitalia of female patients, as indicated by the absence of ambiguity of external genitalia (18 -25 and references therein).
The salt-losing form of classic 3␤HSD deficiency is usually diagnosed during the first few months of life due to insufficient biosynthesis of aldosterone and consequent salt loss that may be fatal if not diagnosed and treated early (16, 25, 26 -30) . In contrast, the nonsalt-losing form of 3␤HSD deficiency may be diagnosed either at a young age in the presence of indicating factors, such as a family history of death during early infancy (31) , perineal hypospadias in male newborns (32, 33) , or failure to gain weight (29) , or the diagnosis may be made at a later age (30, 34 -36) . Due to the fact that sexual differentiation is normal in female newborns affected by nonsalt-losing 3␤HSD deficiency, the proper diagnosis is delayed until adrenarche (35) or puberty (36) .
An elevated ratio of ⌬ 5 -to ⌬ 4 -steroids is considered the best biological parameter for the diagnosis of 3␤HSD deficiency (37, 38) . It is well recognized, however, that levels of 17OH-PROG and ⌬ 4 -DIONE plasma and other ⌬ 4 -steroids are frequently elevated in 3␤HSD-deficient patients (17-25, 26, 27, 34 -38) . Such observations are consistent with a functional 3␤HSD type 1 that is expressed in peripheral tissues and is responsible for the extra-adrenal and extragonadal conversion of ⌬ 5 -hydroxysteroid precursors into the corresponding ⌬ 4 -3-ketosteroids. This peripheral 3␤HSD activity could well explain why some patients were misdiagnosed as having 21-hydroxylase deficiency, in view of elevated 17OH-PROG and mild virilization of girls at birth (21) .
The significant peripheral conversion of ⌬ 5 -hydroxysteroids in 3␤HSD-deficient patients is in agreement with the finding that a large proportion of androgens (about 40% in men) and the majority of estrogens formed in children and in anovulatory or postmenopausal women arise from extragonadal steroidogenesis (for review see Ref. 39 ). However, although very low levels of type 1 3␤HSD messenger RNA (mRNA) can be detected in normal gonads by sensitive ribonuclease protection assay, ⌬ 4 steroids can originate from gonadal 3␤HSD type 1 activity, which possesses a roughly 10-fold higher affinity than the type 2 isoenzyme and which could be stimulated after an increase in LH secretion, resulting from low-circulating androgen levels at puberty (8, 18, 40) . Indeed, a male affected with proven severe 3␤HSD deficiency has fathered children (18, 26) .
The nonclassical form of 3␤HSD deficiency, also referred to as attenuated or late-onset deficiency has been described in older females with hyperandrogenism beginning at adulthood and children with premature pubarche presumed to have nonclassical 3␤HSD deficiency (41) (42) (43) (44) . No mutations were found in both HSD3B1 and/or HSD3B2 genes in these patients (45) (46) (47) , and on reexamination some patients no longer showed an elevated ⌬ 5 /⌬ 4 ratio (45). Moreover, Morel's group also found no mutation in both HSD3B1 and HSD3B2 genes in 20 girls having a 17OH-PREG peak after ACTH stimulation between 30 and 90 nmol/L (21, 48, 49) . It has been concluded that it is difficult, if not impossible, to provide any kind of accurate statement regarding the clinical features, pathophysiology, or diagnosis (50) .
To date, 24 mutations (1 splicing, 3 nonsense, 3 frameshift, and 17 missense mutations) in the HSD3B2 gene were detected from approximately the same number of families with individuals suffering from classical 3␤HSD deficiency (6, 21, 23, 24 , and references therein; Alos, N., Moisan, A.M., Ward, L., et al., submitted for publication). In addition to providing a molecular explanation for the heterogeneous clinical pre-sentations, the functional characterization of these mutant enzymes also generated valuable information concerning the structure-function relationships of the 3␤HSD superfamily (6, 21) . In this regard, the goal of the present study was 2-fold. First, we now report the identification of eight mutations in the HSD3B2 gene in 11 patients suffering from classical 3␤HSD deficiency originating from seven new families. Five of these families were referred to Morel's molecular diagnostics laboratory in France (49) , whereas the other two families were investigated by Peter's group in Germany. Once the mutations had been identified by these two European laboratories, experiments were designed to assess the effect of these mutations on the expression and activity of the 3␤HSD type 2 to gain a better understanding of not only the relation between the molecular defect and the phenotypic manifestation of classical 3␤HSD deficiency, but also on the structure-function relationships of this isoenzyme. Second, in addition to these mutations reported herein, we have also studied the functional significance of recently reported missense mutations and or sequence variants-namely, A82T (51), A167V (52), L173R (22) , L205P (53), S213G and K216E (54), P222H (55) , and T259R (56)-that have not previously been functionally characterized. To perform a consistent and more comprehensive study into the effects of missense mutations in the HSD3B2 gene, we have also reassessed using the current experimental procedures the activity and expression of previously reported mutant enzymes, including A10E (Alos, N., Moisan, A.M., Ward, L., et al., submitted for publication), G15D (57), N100S (58), L108W (61), G129R (60), E142K (19) , P186L (59), A245P (19) , Y253N (19) , and Y254D (61) . The present study, therefore, provides evidence supporting the involvement of a new molecular mechanism in classical 3␤HSD deficiency and further illustrates the complexity of the genotype-phenotype relationship of this disease.
Subjects and Methods Patients
Our study examined seven unrelated families, four of which were affected by the severe salt-losing form of classical 3␤HSD deficiency, whereas three other families were found to be affected by the nonsaltwasting form of classical 3␤HSD deficiency. As indicated in Table 1 , three of the families are French (families 9, 14, and 21), two families originated from Sri-Lanka with one now living in France (family 11), and the other family lives in Germany (family 12). One family originated from Algeria (family 7), whereas the last family was from Egypt (family 16). Families 7, 9, 11, 14, and 21 were referred to Dr. Y. Morel's laboratory for molecular diagnosis, whereas families 12 and 16 were referred to Dr. M. Peter's laboratory.
Cases suffering from the severe salt-wasting form of classical 3␤HSD deficiency
Family 7: The two Algerian siblings have been followed by Dr. D. Barama (Algeria). Patient 8 was noted to have perineal hypospadias with micropenis and palpable testes within the scrotum at birth. The karyotype of this individual was established to be 46XY. The index case underwent a salt-wasting crisis and was started on substitutive glucocorticoid and mineralocorticoid therapy. At 16 months of age, while undergoing treatment, the patient had a bad compliance, 17OH-zPREG levels were found to be severely elevated at a value of 461.6 nmol/L, whereas 17OH-PROG levels were 3.9 nmol/L. Patient 9, a 46XX individual, was found to have mild clitoromegaly at 1 month of age. This individual underwent a salt-wasting crisis and was first misdiagnosed to be suffering from the salt-wasting form of 21-hydroxylase deficiency. At 9 months of age, while undergoing substitutive glucocorticoid and mineralocorticoid therapy, 17OH-PREG levels were still found to be elevated 195.18 nmol/L, whereas 17OH-PROG levels were 5.59 nmol/L.
Family 9: The affected individuals from the French family 9 have been followed by Dr. J. L. Chaussain (Paris, France). Patient 11, a 46XY individual is the eldest of two siblings. His younger sister had normal external genitalia at birth (patient 12), while at birth the index case had perineal hypospadias with palpable testes within the bifid scrotum. At 2 days of age, 17OH-PREG levels were found to be severely elevated at a value of 712.66 nmol/L, whereas 17OH-PROG levels were 105.87 nmol/L, indicative of the blockade of adrenal and gonadal 3␤HSD activity. Sodium and potassium levels were found to be normal until day 10 when a salt-losing crisis occurred (Na ϩ : 132 mmol/L; K ϩ : 5.5 mmol/L; renin levels were also increased to 148 pg/mL). The individual responded well to substitutive glucocorticoid and mineralocorticoid therapy, and by day 81 17OH-PREG levels had fallen to 390.91 nmol/L and 17OH-PROG levels were 75.625 nmol/L. The patient is currently continuing with this therapeutic regime. Family 12: The index case of this family, also originating from SriLanka, was clinically diagnosed by Dr. Peter Beyer (Kinderklinik, Germany), and diagnosis was confirmed by Drs. M. Peter and M.G. Sippell (Kiel, Germany). Patient 16, was born in January 1998 and at birth was noted to have perineal hypospadias. Karyotype analysis determined this individual to be 46XY. Although the consanguinuity of the parents remains unknown, they were both found to be heterozygous for the identified mutation. During the 1st week of life the patient underwent a salt-wasting crisis (Na ϩ : 128 mmol/L; K ϩ 7.5 mmol/L), and based on first hormonal analysis the exact cause of this salt-wasting form of CAH was difficult to determine. Subsequent genetic analysis confirmed 3␤HSD deficiency, and at 9 months of age the patient was successfully treated with substitutive therapy.
Cases suffering from the nonsalt-wasting form of classical 3␤HSD deficiency
Family 14: For both patients 18 and 19, the clinical data has previously been reported as patients 4 and 5, respectively, in Gendrel et al. (32) ; patient 18 also corresponds to patient 4 in Chaussain et al. (62) . Both patients 18 and 19 have a 46XY karyotype and were noted to have perineal hypospadias with palpable testes within the scrotum at birth. Patient 18 had at 6 days of age diarrhea with low plasma sodium levels (130 mmol/L), and moderate salt-loss occurred (urinary Na ϩ 17 mmol/ 24h, under a sub-normal sodium diet 10 -15 mmol/day). At day 12, DHEA levels were recorded as 58.94 nmol/L; ⌬ 4 -DIONE: 5.23 nmol/L; DHEA/⌬ 4 -DIONE ratio as 11.3, no neonatal peak of testosterone was recorded. The patient failed to thrive and was started on substituve therapy. Patient 19 was the eldest of the two siblings. At 8 days of age diarrhea with normal plasma sodium, but with subclinical salt-loss, occurred (urinary Na ϩ : 8 mmol/day, under a normal sodium diet 5.5 mmol/day). Normal growth without any treatment occurred until 3 yr, 10 months of age when the youngest sibling (patient 18) was diagnosed to be suffering from 3␤HSD deficiency. At that point in time, DHEA levels were found to be 40.22 nmol/L; ⌬ 4 -DIONE 1.57 nmol/L, ratio DHEA/⌬ 4 -DIONE 25.6; renin Ͼ13.20 g/L.h). In addition, there was no evidence of an increase in T levels after an hCG test. 
Methods

Selective PCR amplification of HSD3B2 gene fragments
Selective amplification of the HSD3B2 gene fragments was performed as described previously (18, 19) . Three different primer pairs for HSD3B2 were used for amplification of the coding region and the exon-intron splicing junction boundaries. The primers used for PCR amplifications are the same as those used previously (18) .
Direct sequencing of PCR products
Direct sequencing of PCR products was performed as described previously (63) . Briefly, PCR products were purified with microspin S400-HR columns (Pharmacia Biotech, Uppsala, Sweden) to remove salt, residual primers, and unincorporated deoxynucleotide triphosphates. Approximately 80 -100 ng PCR products were directly sequenced using the AmpliTaq FS dye terminators kit (PE Applied Biosystems, Foster City, CA). Each exon was sequenced on both strands. After 25 cycles in 9600 GeneAmp (PE Applied Biosystems; (30 sec at 95 C and 4 min, 30 sec at 60 C), the reaction products were purified on sephadex G50 microspin columns, dried under vacuum, and dissolved in 4 l of a (5:1) formamide:EDTA mix. Electrophoresis was performed with a 7% acrylamide/bisacrylamide 19/1 sequencing gel during 10 h with a 373A model automatic sequencer, and the data were analyzed using Sequed software (Applied Biosystem).
The above methodology was used for all the patients, except patients 16, 22 and 23. For these two patients the nucleotide sequence of both strands of the PCR products were directly determined by thermo-cycle sequencing using the Thermo Sequenase radiolabelled terminator cycle sequencing kit, following the manufacturers instructions (USB Corporation, Cleveland, Ohio), as described previously (64) . The primers used were the same as those used previously (18) .
Site-directed mutagenesis
The oligonucleotide sequences for each mutation were designed such that the desired mutation was in the middle of the primer with 15 bases of correct sequence on either side. Site-directed mutagenesis was performed using the QuickChange Site-directed mutagenesis kit form Stratagene Cloning Systems (La Jolla, CA), according to the supplier's protocol. The correct sequence for each mutation was confirmed by manual sequencing using the dideoxy nucleotide chain termination method (65) using a T7 sequencing kit from Amersham Pharmacia Biotech, Inc. (Picastaway, NJ).
Transcription/translation
Transcription/translation was performed using the TNT Quick coupled transcription/translation system from Promega Corp. (Madison, WI), according to the manufacturer's instructions. Briefly, 0.5 g DNA was added to a 16-l master mix and 1 Ci [
35 S]-methionine; this was then mixed and incubated at 30 C for 90 min, after which the samples were placed on ice. Translation was then assessed by separation on a 12% SDS-PAGE gel, the gel was dried using a gel dryer, followed by exposure to Hyperfilm-MP x-ray film overnight.
Cell culture and transfection
All media and supplements for cell culture were purchased from Life Technologies, Inc. (Grand Island, NY), except FCS, which was purchased from HyClone Laboratories, Inc. (Logan, UT). Human embryonic kidney 293 cells were obtained from the American Type Culture Collection (Manassas, VA) and were cultured in DMEM/low glucose supplemented with 10% FCS, 1% glutamine, 100 IU/mL penicillin, and 50 g/mL streptomycin until confluence. The cells were passaged and plated in 6-well plates at a density of 450,000 cells per well. The cells were allowed to settle overnight, after which the medium was changed to DMEM without any supplements just before transfection. Transient transfection was performed using ExGen 500 cationic polymer transfection reagent (MBI Fermentas Inc, Ontario, Canada), according to the supplier's protocol. Transfection efficiency was monitored by cotransfecting with ␤-galactosidase, the activity of which was assessed using the chemiluminescent reporter gene assay system from Tropix Inc. (Bedford, MA). Cells were also transfected with the pCDNA 3 vector to act as a negative control. One day after transfection the cells were incubated with substrate to assess enzyme activity, as detailed below.
Northern blot analysis
Total RNA was prepared from the transfected cells using TRI Reagent and a modified single-step method based on that of Chomczynski and Sacchi (66) . For Northern analysis, 3 g RNA was loaded per lane and subjected to electrophoresis in a 1% agarose gel containing 2% formaldehyde in 1X [N-morpholino]propanesulfonic acid buffer. The gel was then transferred by capillary action to GeneScreen Plus hybridization transfer membrane (NEN Life Science Products, Inc., Boston, MA), and RNA was immobilized by ultraviolet-cross-linking. Hybridization was performed using an ␣-[
32 P]dCTP-labeled 448-bp fragment of 3␤HSD type 2 generated by PCR, in 50% formamide-containing buffer at 42 C, according to the membrane suppliers protocol. The membranes were washed 2ϫ standard saline-citrate (SSC) (1ϫ SSC ϭ 150 mm sodium chloride, 15 mm tri-sodium citrate) at room temperature for 10 min, and once in 2ϫ SSC/1% SDS at room temperature for 10 min, followed by 2ϫ SSC/1% SDS at 52 C for 10 min. Control hybridization was performed by cohybridization with a human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) complementary DNA (cDNA) HindIII-XbaI fragment of 548 bp. Membranes were exposed to Hyperfilm-MP x-ray film at -80 C for 4 -16 h.
Western analysis
Western analysis of proteins, prepared from transiently transfected 293 cells, was performed by SDS-PAGE on discontinuous acrylamide gels. Samples were prepared for loading by denaturing at 95 C in 2% SDS, 10% glycerol, 62.5 mmol/L Tris (pH 6.8), and 0.1% dithiothreitol and electrophoresed at 200 volts through 4% stacking and 12% resolving gels using the Mini-Protean II Western apparatus (Bio-Rad Laboratories, Inc., Richmond, CA). Total protein (25 g) was loaded per lane, and prestained molecular weight markers (Bio-Rad Laboratories, Inc.) were run in parallel lanes. After electrophoresis, proteins were transferred to Hybond-ECL nitrocellulose membrane (Amersham Pharmacia Biotech 
Assay of 3␤HSD type 2 enzymatic activity
To determine 3␤HSD type 2 enzyme activity in intact 293 cells transiently transfected with the mutant cDNAs, the cells were incubated for 0.5-6 h with 10 nm [4- 14 C(N)-DHEA (55.2 mCi/mmoL), as described previously (57) . Steroids were extracted from the media by the addition of 4 volumes of diethyl ether, and the incubation mixture was chilled in a dry-ice/ethanol bath. Steroids were separated by thin-layer chromatography using a mobile phase of toluene:acetone (4:1) and analyzed using a Phosphorimager imaging system (Molecular Dynamics, Inc., Sunnyvale, CA). All results are expressed as the mean Ϯ se of at least two separate transfection experiments performed in triplicate.
Establishment of apparent K m and V max
The transiently transfected cells were incubated with 10 nm up to 50 m DHEA, including 10 nm [4-14 C(N)]-DHEA and various concentrations of unlabeled DHEA for 15 min (wild-type, A167V, L236S), 30 min (L173R, K216E, S213G), 1 h (A10V, A245P, G294V), 2 h (G129R), or 3 h (A82T) to establish the apparent K m and V max for each mutant compared to the wild-type. Steroid measurement was performed as described in the previous section. Under the conditions used, first order kinetics were always maintained. All results are expressed as the mean Ϯ se of at least three separate experiments performed in triplicate. The apparent K m and V max for each mutant protein were calculated using the ENZFITTER software (Biosoft, Cambridge, UK), as described previously (67) .
Results
Identification of mutant HSD3B2 alleles
To identify the molecular lesion(s) in the HSD3B2 gene in patients from the seven new families suffering from classical 3␤HSD deficiency, the complete nucleotide sequence of the whole coding region and exon-intron splicing boundaries of this gene was determined by direct sequencing, as described in the previous section. The molecular diagnostic testing for patients from families 7, 9, 11, 14, and 21 were performed in Dr. Y. Morel's laboratory (Lyon, France), whereas those from families 12 and 16 were tested in Dr. M. Peter's laboratory (Kiel, Germany).
Molecular testing for the Algerian family 7 revealed in the two salt-wasting patients 8 and 9, the presence in exon IV in the HSD3B2 gene of a homozygous C to A transversion converting codon 222 encoding a Pro residue (CCA) to CAA encoding a Gln residue.
Elucidation of the sequence of exon IV in the HSD3B2 gene from two other salt-wasting patients 11 and 12 from the French family 9 indicated the presence of a heterozygous C to T transition converting codon 259 (ACG) encoding Thr to ATG encoding Met. The frameshift mutation, 867delG was identified in the other allele. This mutation resulting from a deletion of a G in codon 290 would lead to a predicted truncated protein of 299 amino acids (including the first Met).
Independent molecular testing by the two European laboratories of the two male pseudohermaphrodite salt-wasting patients 15 and 16, from families 11 and 12, which originate from Sri-Lanka, revealed the presence of a 27-bp deletion in exon IV deleting the terminal base pair of codon 229 and all of codons 230 -237, in addition to the first two base pairs of codon 238. This deletion did not alter the reading frame, but deleted the amino acid residues Ala-His-Leu-Ala-Leu-ArgAla. Both the individuals identified to be carrying this mutation were homozygous, whereas their parents were found to be heterozygous.
Following direct sequencing of exon IV in the HSD3B2 gene of the two male nonsalt-wasting pseudohermaphrodite patients 18 and 19 of the French family 14, the presence of a C to T transition was identified in the maternal allele converting codon 155 (CCG) encoding a Pro to CTG encoding a Leu. However, a G to T transversion was identified in the paternal allele converting codon 294 (GGC) encoding a Gly residue to GTC encoding a Val.
Direct sequencing of exon II of the HSD3B2 gene in the two Egyptian pseudohermaprodite patients 22 and 23 from family 16, who are suffering from a nonsalt-wasting form of 3␤HSD deficiency, revealed the presence of a homozygous C to T transition converting codon 10 (GCA) encoding an Ala residue to GTA encoding a Val residue. In addition, this mutation was found in the heterozygous state in both parents.
Finally, the presence of a heterozygous T to C transition converting codon 236 encoding a Leu (TTG) to TCG, encoding a Ser residue, was found in the HSD3B2 gene of the nonsalt-wasting male pseudohermaphrodite patient 32 from the French family 21. We have also identified in his other allele the frameshift mutation 867delG, which was previoulsy observed in the other French family 9.
Effect on 3␤HSD activity of the in-frame deletion 687del27 and of all missense mutations found in patients suffering of the severe salt-wasting form of 3␤HSD deficiency.
Site-directed mutagenesis for each of the mutants was performed as detailed in Methods, and sequence analysis was performed to confirm that the correct substitution or deletion had been achieved for each mutant cDNA construct. Following transient transfection of each mutant construct in 293 cells, the effect of the various mutations on enzyme activity was assessed by incubating intact cells in culture with 10 nm [ 14 C]-DHEA as substrate for the indicated time periods. Such analyses were performed at least in two independent transfection experiments done in triplicate.
For the first time, we have characterized the effect of mutations L205P, P222Q, T259M, T259R, and 687del27 on 3␤HSD activity in comparison to the effect on all other reported missense mutations found in patients suffering from the severe salt-wasting form of 3␤HSD deficiency ( Table 1) . As illustrated in Fig. 1 , no significant transformation of [ 14 C]-DHEA was observed in intact cells transfected with plasmid constructs expressing mutated recombinant A10E, G15D, L108W, E142K, P186L, L205P, P222Q, Y253N, T259M, T259R, and 687del27 proteins. Northern blot analyses demonstrated that both wild-type and mutant transcripts were expressed at equal levels in transfected 293 cells, whereas no significant endogenous type II 3␤HSD mRNA (1.7 kb) was detected in mock pCDNA 3 transfected cells, thus confirming the effi- ciency of 3␤HSD transcription from the adenoviral promotor of the vector. Cohybridization to GAPDH was performed to determine equal loading of RNA for each sample.
On the other hand, it is expected that the W171X and 558insC mutations (18, 19) , as well as the novel 867delG mutation, will lead to putative truncated proteins possessing no 3␤HSD activity. Therefore, our results suggest the absence of functional 3␤HSD type 2 isoenzyme in the adrenals and the gonads of the patients from families 1 to 12 indicated in Table 1 , which is in consistent with the severity of the disorder in these index cases.
Effect on 3␤HSD activity of all missense mutations found in patients suffering from the nonsalt-wasting form of 3␤HSD deficiency
Following the same experimental procedures described above, we next characterized for the first time the functional significance of the missense mutations A10V, A82T, P155L, L173R, L236S, P155L, P222H, and G294V (Table 1 ; Fig. 1 ). To perform a consistent and more comprehensive study, we have also reassessed, using the current experimental procedure, the activity of previously reported mutant enzymes detected in patients affected by the nonsalt-wasting form of the disease (19, 58, 60) , including N100S, G129R, A245P, and Y254D.
As illustrated in Fig. 1 , no significant conversion of [ 14 C]-DHEA was obtained in intact 293 cells transfected with plasmid constructs expressing mutated recombinant P155L, P222H or Y254D proteins. It can also be seen that in cells transfected with pCDNA 3 -G294V or pCDNA 3 -G129R, the apparent activity after a 1-h incubation (percent conversion of [
14 C]-DHEA in cells transfected with each vector expressing the mutant protein/% conversion of [
14 C]-DHEA in cells tranfected with pCDNA 3 -3␤HSD type 2 ϫ 100) were 20.5% and 11.7%, respectively. The in vitro results obtained in intact cells suggest that the combined residual activity catalyzed by these mutant type 2 enzymes approximates to 10.25% (P155L/G294V) and 5.85% (P222H/G129R). However, as described below, another mechanism(s) might affect such residual activity.
In 293 cells tranfected with pCDNA 3 -A10V, pCDNA 3 -A82T, pCDNA 3 -N100S, pCDNA 3 -L173R, or pCDNA 3 -A245P, the apparent residual activities after a 1-h incubation were 29.1%, 7.6%, 2.8%, 52.8%, and 35.4%, respectively. All these mutant alleles were detected in the homozygous state. Surprisingly, the activity of the mutant recombinant L236S protein, which was found in the compound heterozygous patient 32 (L236S/867delG), was almost superimposable with that of the wild type 3␤HSD type 2 isoenzyme. Unexpectedly, no significant activity up to a 4-h incubation was observed with the T259M mutant protein, which was identified in the homozygote nonsalt-losing 46XX individuals (patients 35 and 36), although low, but not significant, activity was observed after 6-h incubation (Fig. 1) .
Effect on 3␤HSD activity of sequence variants found in carriers with the nonclassic form of 3␤HSD deficiency
Several sequence variants and/or mutations (A167V, S213G, K216E, and L236S,) were detected with premature pubarche or hyperandrogenic adolescent girls suspected to be affected from nonclassical (late-onset) 3␤HSD deficiency (52, 54) . To gain further knowledge concerning the molecular basis of such a disorder we next investigated the apparent activity of these mutant enzymes. In 293 cells transfected with pCDNA 3 -A167V, pCDNA 3 -S213G, pCDNA 3 -L236S, or pCDNA 3 -A245P, the apparent residual activities after a 1-h incubation were 81.45%, 58.4%, 58.95%, and 100%, respectively. Knowing that all previously reported heterozygous carriers bearing a deleterious mutation in the HSD3B2 gene were typically asymptomatic, these results provide additional molecular proof to support the conclusion that other genetic or environmental/hormonal influences may contribute to the expression of the observed symptoms (45, 48, 49, 50, 52, 68) .
Kinetic analysis of mutant proteins
After the initial assessment of the effect of the various mutations on enzyme activity, the mutations that were found to retain activity were further analyzed to gain more information about the apparent K m and V max for each mutant enzyme. The transiently transfected cells were incubated with various concentrations of DHEA ranging from 10 nm-50 m (using 10 nm [
14 C]-DHEA), under conditions ensuring that first order kinetics were maintained. These analyses were performed during at least three independent tranfection experiments, in triplicate. The results, as shown in 
Evidence of the instability of several mutant proteins
In the past few years, we have frequently observed that it is difficult, if not impossible, to detect certain transiently expressed mutant recombinant proteins by Western blot analysis. The next study was designed to gain further biochemical data concerning this phenomena. We thus compared the levels of expression and stability of 25 mutant recombinant 3␤HSD type 2 proteins. As illustrated in Fig. 3A , all transcripts were expressed in transfected 293 cells following transient expression with the indicated expression vector constructs, as revealed by Northern blot analysis. The cells were also transfected with the pCDNA 3 vector alone to show no endogenous expression of 3␤HSD type 2 mRNA. (L173R, K216E, S213G ), 1h (A10V, A245P, G294V), 2h (G129R) or 3h (A82T) to establish the apparent K m and V max for each mutant protein compared to the wild-type. The data are displayed as LineweaverBurk plots. Under the conditions used, first-order kinetics were always maintained. The results are expressed as the mean Ϯ SE of at least three separate transfection experiments performed in triplicate, with the exception of data obtained with A245P, which has been performed on a single occasion. The relative expression levels for all constructs have been confirmed by Northern blot analysis, as described in the legend for Fig.  1 , thus, the V max values were calculated using the amount of total cellular protein in each corresponding petri dish after transfection experiments.
The transfection efficiency has also been confirmed by using human GAPDH as a control. In parallel, an in vitro transcription/translation (TNT) rabbit reticulocyte lysate assay using the mutant cDNA constructs was performed to show that each pCDNA 3 construct is adequately translated into a [ 35 S]-labeled-42-kDa protein, indicative of the normal expression levels of mutant recombinant 3␤HSD type 2 proteins. To determine whether all mutant proteins are, indeed, recognized by our polyclonal antibodies, Western blot analysis of the corresponding samples from the TNT assay were hybridized with an antihuman 3␤HSD type 1 antibody. The data illustrated in Fig. 3B support the notion that there is no detectable change on the polyclonal antibody binding site as a consequence of these mutations. We have then performed Western blot analysis using the homogenates purified from the same cells transfected with the indicated expression vector constructs, which have been used for RNA blot analysis illustrated in Fig. 3A . A 42-kDa band corresponding to the 3␤HSD type 2 protein was detectable in several but not all homogenate preparations from 293 transfected cells expressing the indicated wild type or mutant recombinant proteins. The nonspecific band observed may also be used as an internal control for loading. Such a difference in immunoblot signal levels has been observed in several independent experiments.
Discussion
The present study describes the identification of eight mutations, in seven families with individuals suffering from classical 3␤HSD deficiency, thus increasing the number of known HSD3B2 mutations involved in this autosomal recessive disorder to 31 (1 splicing, 1 in-frame deletion, 3 nonsense, 4 frameshift, and 22 missense mutations). In addition to providing further molecular explanations for the heterogeneous clinical presentations, the functional characterization of these mutant enzymes also generated valuable information concerning the structure-function relationships of the 35 S]-labeled-42kDa protein, indicative of the normal expression levels of mutant recombinant 3␤HSD type 2 proteins. Translation was assessed by separation on a 12% SDS-PAGE gel. To determine whether all mutant proteins are recognized by the polyclonal antibody, Western blot analysis of the corresponding samples from the TNT assay, probed with an antihuman 3␤HSD type 1 polyclonal antibody at 1:2000 dilution was performed as described in Methods. C, Western blot analysis of the homogenates purified from the same corresponding transiently transfected 293 cells with the indicated expression vectors, which have been used for RNA blot analysis illustrated in the panel A. A 42-kDa band coresponding to the 3␤HSD type 2 protein was detectable in several but not all homogenate preparations from 293 transfected cells expressing the indicated wild type or mutant recombinant proteins, whereas no 42-kDa protein is detected in cells transfected with the mock pCDNA 3 vector alone. The nonspecific band observed may also be used as an internal control for loading.
3␤HSD superfamily. Indeed, in addition to these mutations reported herein, we have also studied for the first time the functional significance of previously reported missense mutations and or sequence variants-namely, A82T (51), A167V (52), L173R (22) , L205P (53), S213G and K216E (54), P222H (55) T259M (55) , and T259R (56)-that have not previously been functionally characterized. Furthermore, their effects have been compared to those of previously reported mutant enzymes, including A10E (Alos, N., Moisan, A.M., Ward, L., et al., submitted for publication), G15D (57), N100S (58), L108W (59), G129R (60), E142K (19) , P186L (59), A245P (19) , Y253N (19) , and Y254D (61) to provide a more consistent and comprehensive study with the same experimental procedures using transfected intact 293 cells (Table 1) . Finally, the present study, therefore, provides evidence supporting the involvement of a new molecular mechanism in classical 3␤HSD deficiency involving protein instability and further illustrates the complexity of the genotype-phenotype relationships of this disease.
Our present data further support the fact that it is more appropriate to assess the enzymatic activity of transiently expressed mutant proteins using intact 293 cells rather than homogenates from cells, due to the fact that the addition of exogenous cofactor can drive a reaction that may not occur in vivo. This conclusion is also consistent with our previous report showing that the homozygous mutation G15D found in a patient suffering from a severe salt-wasting form completely abolished the activity of the transiently expressed mutant protein in intact cells, whereas a significant residual activity was observed when using cell homogenates (57) . The use of an excess of exogenous cofactor in studies using cell homogenates was responsible, at least in part, for this apparent discrepancy because this mutation, which is located in the NAD-binding domain, markedly decreases the affinity for the cofactor. The mutations N100S, L108W, and P186L also severely affected the affinity for the cofactor (57, 58) . The advantage in using intact cells to assess the enzymatic characteristics was also indicated by several studies describing the properties of numerous hydroxysteroid dehydrogenases. For example, the type 1 isozyme of 11␤-hydroxysteroid dehydrogenase was always thought to act as both a dehydrogenase and an oxoreductase, and it was not until assessment of enzyme activity in intact cells (79 and references therein) that it became apparent that this isozyme behaves as a reductase in vivo, but in vitro can also act as a dehydrogenase due to the addition of exogenous cofactor (79 and references therein). A similar conclusion has been proposed concerning members of the 17␤HSD family (80) . Furthermore, it was recently shown that the activity of the type 5 isozyme of 17␤HSD was unstable when assessed in homogenates of transfected cells as compared to assessment when using intact cells (81) . However, we have previously observed in cells expressing the mutant protein A245P that no activity was obtained in cell homogenates in the absence of glycerol, whereas significant activity could be measured in intact cells (19) .
Although the exact molecular and cellular explanation for the apparent instability of various mutant recombinant proteins in intact transfected 293 cells remains to be elucidated, our results illustrate that it might be difficult, if not impossible, to rigorously measure the levels of expression of some of these mutant proteins to obtain an accurate estimate of their V max value. We are, thus, suggesting that the various degrees of protein instability may explain, at least in part, not only the observed decrease in the V max values for several mutant proteins and more specifically for those with the L173R or G294V substitution, but also the absence of activity observed in 293 cells transiently expressing mutant recombinant proteins A10E, G15D, L108W, P186L, A245P, Y253N, T259M, and T259R. For example, although the overall efficiency of the N100S protein found in the homozygous nonsalt-loser patient 17 (58) is closely similar (ϳ0.1%) to that of L108W and P186L found in the compound heterozygous salt-loser patient 4 (59) The present study illustrates the inherent limitations of such experimental approaches that should be used in conjunction to further evaluate the impact of a mutation on in vivo enzymatic activity. It should be noted that, although the values obtained in the assessment of apparent K m and V max in this study are consistent with those of previously published mutations (60) , throughout these studies we have assessed enzyme activity for all the mutants in intact cells to most resemble the situation in the cells of the patient. In fact, the present results, thus, suggest that a single amino acid substitution can alter the phenotypic expression of a protein by altering its stability. In agreement with this finding, it has previously been shown that a single amino acid mutation in Cytochrome P450 (P4502C13), namely Ser 180 to Cys, located in a highly conserved region in the P4502C subfamily, determines a polymorphism by altering protein stability (82) .
The present study is also in agreement with the prediction that no functional 3␤HSD type 2 isoenzyme is expressed in the adrenals and gonads of the patients suffering from a severe salt-wasting form of CAH due to classical 3␤HSD deficiency, as summarized in Table 1 . Note that the 10 patients suffering from a severe salt-wasting form of 3␤HSD deficiency, who bear homozygous [W171X (18) , R259X (40, 56) , Y308X (56), 820delAA (77) ] or compound hetrozygous [W171X/558insC (18) , 820delAA/952delC (78)] mutations, were not included in Table 1 . It has been predicted that these nonsense and frameshift mutations lead to nonfunctional truncated proteins. Taken together, all these results are in perfect agreement with the severity of this form of CAH. On the other hand, the observed peripheral conversion of ⌬ 5 -hydroxysteroids in these patients is consistent with the now recognized important biosynthesis of sex steroids in peripheral tissues (39) . However, although very low levels of 3␤HSD type 1 transcripts can be detected in normal gonads, ⌬ 4 steroids can originate from gonadal 3␤HSD type 1 activity, which possesses a roughly 10-fold higher affinity than the type 2 isoenzyme and which could be stimulated after an increase in LH secretion, resulting from low-circulating androgen levels at puberty (8, 18, 40) .
In addition, the present study demonstrates that the nonsalt-losing form of classic 3␤HSD deficiency also results from missense mutation(s) in the HSD3B2 gene, which causes an incomplete loss of enzymatic activity, thus leaving sufficient enzymatic activity to prevent salt wasting (19, 58, 60) . On the other hand, it is worth noting that the kinetic properties of the N100S protein, found in a nonsalt-losing patient (58) are quite similar to those of L108W and P186L mutant proteins, which were detected in a severe salt-losing form of classical 3␤-HSD deficiency (59) when kinetic properties were measured using cell homogenates. The functional characterization of these mutant proteins in cell homogenates cannot provide an explanation for the heterogeneity responsible for the severe salt-losing form (L108W:P186L) down to the clinically inapparent form of salt loss (N100S) of classic 3␤HSD deficiency; nevertheless, the hormonal profile of the N100S mutation suggests that salt loss was compensated for by a limited capacity of aldosterone biosynthesis at the price of high renin synthesis (Table 1 ). In addition, the present data suggesting the instability of L108W and P186L, but not of N100S, may well explain, at least in part, the observed difference in the levels of activity using intact cell assays which is in accordance with the phenotypic differences observed in these two patients.
It is also of interest to mention that the striking phenotypic differences observed between the homozygous salt-losing patients 1 and 2, bearing the A10E mutation (Alos, N., Moisan, A.M., Ward, L., et al., submitted for publication), and the nonsalt-losing patients 22 and 23, bearing the A10V mutation, is in accordance with their respective enzymatic properties, as determined in intact cells. Such a difference may be the result of both the observed apparent instability of the A10E protein coupled with the fact that Glu is a negatively charged residue, whereas Val, like Ala, is a nonpolar residue. It should also be noted that this Ala is located in the highly conserved putative NAD-binding domain (21, 57, 83, 84) .
In general, the present functional data are in close agreement with the severity of the disease in patients suffering form the nonsalt-wasting form of 3␤HSD deficiency. In this respect, it can be estimated that the 3␤HSD activity catalyzed by the mutant type 2 proteins in the compound heterozygotes P155L/G294V, P222H/G129R and G129R/6651(G to A), as well as the homozygotes A10V, A82T, and A245P will be 10.2, 5.8, 5.8, 29, 7.6, and 35.4%, respectively, as measured in intact cells. On the other hand, knowing that all heterozygote carriers of a deleterious mutation in the HSD3B2 gene are asymptomatic, it was unexpected to observe such a relatively high activity of L173R, i.e. 52.8% (Fig. 1C) , but the apparent instability of L173R would most likely be involved in further reducing the activity catalyzed by the mutant 3␤HSD type 2 protein in the cells of the adrenals and gonads in patients 30 and 31. It is also possible that the apparent instability of A245P and G294V will play a role in further decreasing the activity in patients from families 14 and 22, as also suggested by their V max /K m values.
Although the results described above illustrate very well the almost perfect genotype-phenotype relationships, there are several examples supporting the notion that there are exceptions to the rule. First, the homozygous A82T mutation that was previously reported in four Brazilian patients 24, 25, 26 and 27 (36, 51) . In family 18, it associated with precocious puberty, whereas in the unrelated family 17, it was, indeed, associated with male pseudohermaphroditism, but had no effect in the homozygous female relative. However, it has recently been demonstrated that although the homozygous A10E patient, patient 2, presented with the typical phenotype of ambiguous genitalia at birth with normal masculinization at puberty, the female patient (patient 1) also harboring this homozygous mutation, presented with spontaneous feminization and menarche (Alos, N., Moisan, A.M., Ward, L., et al., submitted for publication), in contrast to the other 46XX patient with severe 3␤HSD deficiency (due to a homozygous W171X mutation), for whom follow-up at pubertal age has been reported, who was hypogonadal (18, 85) . Another astonishing example is the observation that the Brazilian patients 35 and 36 bearing the homozygous mutation T259M suffer from a nonsalt-wasting form of the disease, whereas the compound heterozygous French patients 11 and 12 with T259M/867delG are affected by the severe salt-wasting form. It is, thus, impossible to correlate the phenotype of patients 35 and 36 with the present data showing that cells expressing mutant T259M proteins have no 3␤HSD activity, and in comparison with the T259R mutation, we provide evidence suggesting the instability of the mutant T259M protein.
It was also unexpected to observe that the L236S mutation, which was found in the compound heterozygous nonsaltlosing patient 32 (L236S/867delG), possesses the same enzyme activity as the wild-type enzyme, and, furthermore, there is no evidence that this mutation affects the stability of the protein. Although some genetic alterations affecting the synthesis of a multimeric protein may have a dominant effect (86) , such evidence remains to be demonstrated for the 3␤HSD family. Nevertheless, this hypothesis is, thus, difficult to reconcile with the well established fact that heterozygous carriers are asymptomatic (6, 20 -22) . On the other hand, we cannot rule out that the L236S mutation could be in linkage disequilibrium with another deleterious mutation affecting the expression or the splicing of this gene.
The present study also demonstrates that not only the L236S mutation but also the heterozygous A167V sequence variant leads to proteins that have similar activity to the native enzyme, whereas mutant S213G and K216E proteins had only minor impact on the activity. It should also be noted that the mother of patient 37 was also a heterozygous carrier for this variant, but did not have any symptoms of hyperandrogenism (52) . The present functional data concerning these sequence variants coupled with the previous studies reporting that no mutations were found in both HSD3B1 and/or HSD3B2 genes in the patients affected by premature pubarche or hyperandrogenism (45) (46) (47) (48) (49) 68) , strongly support the conclusion that this disorder does not result from a mutant 3␤HSD isoenzyme. We cannot refute the possibility that inherited mutation(s) could be located farther upstream in the putative promoter region of the HSD3B2 gene, leading to an aberrant level of expression of a normal type II 3␤HSD protein. However, the latter hypothesis is markedly weakened by the fact that all patients come from unrelated pedigrees and diverse ethnic origins. On the other hand, because 3␤HSD gene expression and activity are under complex multiple hormonal regulation (6) , it cannot be ruled out that at least some forms of NC3␤HSD deficiency result from a genetic or acquired origin acting indirectly on these modulatory parameters. There is also the possibility of the implication of a steroidogenic enzyme different from known 3␤HSD isoenzymes. Does it possibly involve dysregulation of 17␣-hydroxylase and 17,20-lyase activities, as has been suggested (87) ? If so, is this dysregulation of genetic origin? All these hypotheses remain to be further studied to gain more understanding of this puzzling but frequent disease.
Finally, the functional characterization of these mutant enzymes also generated valuable information concerning the structure-function relationships of the 3␤HSD superfamily. Indeed, as indicated in Table 1 , of special interest to note is that the amino acid residues that are the sites of the missense mutations are generally in highly conserved regions in members of the vertebrate 3␤HSD isoenzymes characterized thus far in the human, macaque, bovine, rat, mouse, hamster, chicken, and rainbow trout (for a review, see Ref. 21) . This finding strongly suggests the crucial role of these residues for the catalytic activity of these enzymes. However, for example, although amino acid Pro 186 is also well conserved in the vertebrate 3␤HSD family, it is not conserved in all members; namely rat type 3, mouse types 4 and 5 and hamster type 3, which are specific 3-ketoreductases responsible for the conversion of 3-keto-saturated steroids using NADPH as cofactor, which do not share this amino acid residue at this position (6, 21) . It is also of interest to mention that mutations A10E, A10V and G15D change an amino acid in the highly conserved Gly-X-X-Gly-X-X-Gly region found in all members of the 3␤HSD superfamily (89) , which is similar to the common Gly-X-Gly-X-X-Gly conserved sequence present in most NAD(H)-binding enzymes (83, 84) . Moreover, mutations A82T and G294V create a substitution in each of the two predicted membrane-spanning domains (6, 88) . Furthermore, mutation P155L is located in the first of the two the characteristic Y-X-X-X-K sequences located in the region from Tyr 154 to Lys 158 and Tyr 269 to Lys 273 , which is found in the active site of short-chain alcohol dehydrogenases (83, 90) . Affinity labeling of purified human type I 3␤HSD identified two tryptic peptides, comprising amino acids Asn 176 to Arg 186 and Gly 251 to Lys 274 that should contain residues involved in the putative substrate-binding domain (91) . Thus, the exact role of the first YXXXK motif in the 3␤HSD family remains to be confirmed. Finally, recent findings have shown that His 261 is a critical amino acid residue for 3␤HSD activity and Tyr 253 or Tyr 254 participates in the isomerase activity of the human 3␤HSD type 1 enzyme (92, in addition to evidence that Tyr 253 functions as the general acid (proton donor) in the isomerase reaction (93) . Consequently mutations located within this area will inevitably have a major effect on enzyme activity, as exemplified in the case of mutations Y253N, Y254D, T259M, and T259R, which completely abolish enzyme activity.
In summary, these studies have provided further insight into the molecular basis of 3␤HSD deficiency and have highlighted the fact that mutations in the HSD3B2 gene can result in a wide spectrum of molecular repercussions that are associated with the different phenotypic manifestions of classical 3␤HSD deficiency. The present results have also demonstrated the fact that the genotype correlates very well with the phenotype in most cases studied, with the exception of patients 35 and 36 bearing the homozygous mutation T259M, whereas additional studies will be needed to elucidate the real impact of the locus harboring the L236S mutation. Moreover, the present study further demonstrates the importance of the measurement of 17OH-PREG levels, which always exceeded 100 nmol/L in patients suffering from classical 3␤HSD deficiency. The functional characterization of all the missense mutations known to be involved in this disease also provides valuable information concerning the structurefunction relationships of the 3␤HSD superfamily. Finally, the present studies have highlighted the fact that various mutations seem to have a drastic effect on the stability of the protein, thus providing the first molecular evidence of a new mechanism involved in classical 3␤HSD deficiency.
